Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study to Assess the Real-world Effectiveness of EVUSHELD™ (Tixagevimab/Cilgavimab) as Pre-exposure Prophylaxis Against COVID-19 Among EVUSHELD-eligible Populations in the United States Department of Defense Healthcare System

NCT05569408 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05569408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05569408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study to Assess the Real-world Effectiveness of EVUSHELD™ (Tixagevimab/Cilgavimab) as Pre-exposure Prophylaxis Against COVID-19 Among EVUSHELD-eligible Populations in the United States Department of Defense Healthcare System
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
August 10, 2023
Completion date
December 22, 2023
Enrollment
4,724 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19; sars-cov-2; 2019 novel coronavirus disease